Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Traxion Sab De Cv Ord Shs GRPOF

Grupo Traxion SAB de CV is a Mexico-based company engaged in the transportation sector. The Company provides logistics services within eight business areas: Fright, including intermodal and multimodal services, door-to-door, national and cross-border distribution, among others; Integrated logistics, including logistics management, aerial and maritime services and custom transportation support... see more

PINL:GRPOF - Post Discussion

Traxion Sab De Cv Ord Shs > The beauty and the beast,
View:
Post by MichelC58 on Dec 15, 2018 9:38am

The beauty and the beast,

Translated texts
(Some sentences are extracted from texts read while doing some research)
 
Tetra is known to have established a partnership with the American company Rhodes Technologies, a subsidiary of Purdue Pharmaceuticals. Be aware that this ad is HUGE.
 
Who is Purdue Pharma?
It is an unlisted family business. She defines herself as a pioneer in the development of drugs to reduce pain, one of the main causes of human suffering. Purdue Pharma designs painkillers such as codeine, oxycodone, fentanyl, and hydrocodone. On their site, OxyContin is presented as an analgesic reserved for cases of severe pain, especially of cancerous origin. It has generated $ 35 billion in sales since 1995 solely through its star painkiller, OxyContin. Tie yourself the PPP001 arrives.
 
In 1995, the laboratory launched OxyContin, a powerful drug based on pure oxycodone, a cousin of heroin. It is not the first painkiller, but the use was previously reserved for the treatment of severe pain associated with diseases such as cancer. OxyContin has become a drug with huge commercial success.
 
In 2007, Purdue paid one of the heaviest fines ever levied against a pharmaceutical company for labeling and misleading its OxyContin product, with three leaders found to be criminally culpable. Although the company has changed the labeling by warning against the abuse of its products, Purdue continues to market, sell opioids and be involved in the trials around the opioid crisis. Its product oxycodone is considered the main culprit of this crisis.
 
For years, Purdue, who has been sued dozens of times, has defended himself arguing that their product was not in question but rather the use. It is necessary to crush the drug to turn it into a hard drug that can be sniffed or injected. But the packaging of OxyContin could serve as a user's guide: there was a warning that reducing the powdered medicine made it "potentially" toxic.
 
The responsibility of these large groups in the opioid crisis, which causes 145 deaths by overdose each day in the United States according to the authorities, is regularly pointed out. The complaint concerns a dozen laboratories, but one of them occupies a special place in the eyes of specialists in this epidemic: Purdue Pharma.
 
What does Tetra do with this company, moreover, is in the same niche as Purdue, "severe pain"?
Tetra has made major advances both for its PPP001 drug and to strategically position itself on D-Day all over the world. If he succeeds in having his star drug approved by Health Canada and the FDA, we will see the birth of a new company in this world of big pharma.
 
By partnering with Purdue, through her subsidiary Rhodes, Purdue seeks to repair the damage, improve her image, she is still responsible for several deaths a day. Tetra would be a good solution because we know that cannabis can never cause death even if it is abused. A Purdue / Tetra partnership would make society look good for sure, not all companies want to be viewed negatively.
They also do not want to lose money because if PPP001 ever replaces opioids, many companies will be losing revenue, which is why the alternative for Purdue is Tetra.
 
Purdue, through its subsidiary Rhodes, has partnered with Tetra Bio-Pharma for PPP 002/003/004. The press release does not indicate PPP001. But could Purdue keep it for itself? If everything works well for Tetra and its PPP001 and we have a real association with Purdue, we will have there, a major breakthrough in the United States, then around the world.
I may dream, but this vision that I have, seems really plausible.
The beauty and the beast, united, that's not what the story tells !!!
Comment by ogoun60 on Dec 15, 2018 12:05pm
My pesonal research on Dec. 11th lead me to Purdue as well as mentioned in the post below. However, one of the point which catched my attention is the fact that Purdue is ONE OF THE MOST IMPORTANT private company appointed by the TRUMP COMMISSION ON OPIOID CRISIS. This is a MAJOR door opening for Tetra in the "NEW POST OPIOID ERA" if everything goes well for their # DIN. I imagine Purdue ...more  
Comment by LeafRider on Dec 17, 2018 9:32am
This post has been removed in accordance with Community Policy
Comment by gkmackdadzzz1 on Dec 17, 2018 12:05pm
This post has been removed in accordance with Community Policy
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities